Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

280 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prospective comparison of 18F-FDG PET/MRI and 18F-FDG PET/CT for thoracic staging of non-small cell lung cancer.
Kirchner J, Sawicki LM, Nensa F, Schaarschmidt BM, Reis H, Ingenwerth M, Bogner S, Aigner C, Buchbender C, Umutlu L, Antoch G, Herrmann K, Heusch P. Kirchner J, et al. Among authors: umutlu l. Eur J Nucl Med Mol Imaging. 2019 Feb;46(2):437-445. doi: 10.1007/s00259-018-4109-x. Epub 2018 Aug 3. Eur J Nucl Med Mol Imaging. 2019. PMID: 30074073 Clinical Trial.
Correlation of the apparent diffusion coefficient (ADC) and standardized uptake values (SUV) with overall survival in patients with primary non-small cell lung cancer (NSCLC) using 18F-FDG PET/MRI.
Bruckmann NM, Kirchner J, Grueneisen J, Li Y, McCutcheon A, Aigner C, Rischpler C, Sawicki LM, Herrmann K, Umutlu L, Schaarschmidt BM. Bruckmann NM, et al. Among authors: umutlu l. Eur J Radiol. 2021 Jan;134:109422. doi: 10.1016/j.ejrad.2020.109422. Epub 2020 Nov 19. Eur J Radiol. 2021. PMID: 33271432
Impact of EBUS-TBNA in addition to [18F]FDG-PET/CT imaging on target volume definition for radiochemotherapy in stage III NSCLC.
Guberina M, Darwiche K, Hautzel H, Ploenes T, Pöttgen C, Guberina N, Herrmann K, Umutlu L, Wetter A, Theegarten D, Aigner C, Eberhardt WEE, Schuler M, Karpf-Wissel R, Stuschke M. Guberina M, et al. Among authors: umutlu l. Eur J Nucl Med Mol Imaging. 2021 Aug;48(9):2894-2903. doi: 10.1007/s00259-021-05204-7. Epub 2021 Feb 5. Eur J Nucl Med Mol Imaging. 2021. PMID: 33547554 Free PMC article.
Complete metabolic response in patients with advanced nonsmall cell lung cancer with prolonged response to immune checkpoint inhibitor therapy.
Ferdinandus J, Metzenmacher M, Kessler L, Umutlu L, Aigner C, Karl KO, Grünwald V, Eberhardt W, Fendler WP, Herrmann K, Faehling M, Christoph DC. Ferdinandus J, et al. Among authors: umutlu l. J Immunother Cancer. 2021 Mar;9(3):e002262. doi: 10.1136/jitc-2020-002262. J Immunother Cancer. 2021. PMID: 33789880 Free PMC article.
PROGNOSTIC VALUE OF POST-INDUCTION CHEMOTHERAPY VOLUMETRIC PET/CT PARAMETERS FOR STAGE IIIA/B NON-SMALL CELL LUNG CANCER PATIENTS RECEIVING DEFINITIVE CHEMORADIOTHERAPY.
Guberina M, Poettgen C, Metzenmacher M, Wiesweg M, Schuler M, Aigner C, Ploenes T, Umutlu L, Gauler T, Darwiche K, Stamatis G, Theegarten D, Hautzel H, Jentzen W, Guberina N, Herrmann K, Eberhardt WEE, Stuschke M. Guberina M, et al. Among authors: umutlu l. J Nucl Med. 2021 May 20;62(12):1684-91. doi: 10.2967/jnumed.120.260646. Online ahead of print. J Nucl Med. 2021. PMID: 34016730 Free PMC article.
N-staging in large cell neuroendocrine carcinoma of the lung: diagnostic value of [18F]FDG PET/CT compared to the histopathology reference standard.
Hautzel H, Alnajdawi Y, Fendler WP, Rischpler C, Darwiche K, Eberhardt WE, Umutlu L, Theegarten D, Stuschke M, Schuler M, Aigner C, Herrmann K, Plönes T. Hautzel H, et al. Among authors: umutlu l. EJNMMI Res. 2021 Jul 22;11(1):68. doi: 10.1186/s13550-021-00811-9. EJNMMI Res. 2021. PMID: 34292419 Free PMC article.
280 results